Who is sponsoring NCT05422521?

NCT05422521 is sponsored by Centre Hospitalier Universitaire de Nice.

What drugs are being tested in NCT05422521?

Interventions in NCT05422521: blood samples and 18FDG PET-CT exams.

What condition does NCT05422521 study?

NCT05422521 studies Refractory or Relapsed Non-Hodgkin's Lymphoma.

Is NCT05422521 still recruiting?

NCT05422521 is currently status unknown. Last updated 30 January 2024.

Last reviewed 2024-01-30 · How we verify

NCT05422521: CART-Omic

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma

Status unknown NA Last updated 30 January 2024

What this trial tests

NA trial testing blood samples and 18FDG PET-CT exams in Refractory or Relapsed Non-Hodgkin's Lymphoma in 20 participants. Status unknown.

Timeline

29 August 2022

Primary endpoint
28 February 2025

28 February 2026

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Nice
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	20
Start date	29 August 2022
Primary completion	28 February 2025
Estimated completion	28 February 2026
Sites	1 location across France

Drugs / interventions tested

blood samples and 18FDG PET-CT exams

Conditions studied

Refractory or Relapsed Non-Hodgkin's Lymphoma — all drugs for Refractory or Relapsed Non-Hodgkin's Lymphoma →

Sponsor

Centre Hospitalier Universitaire de Nice

Who can join

18 and older, any sex, with Refractory or Relapsed Non-Hodgkin's Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an interventionnal pilot study to investigate whether 18FDG radiomics or serum metabolomic signatures could be predictive or prognostic factors in the follow-up of patients receiving CAR T-cell therapy for refractory non-Hodgkin's lymphoma or in relapse.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Centre Hospitalier Universitaire de Nice trials

Trials by the same sponsor.

NCT05897996 — Percutaneous Anastomosis Creation for Hemodialysis Access · NA · withdrawn
NCT07499869 — INNOVATIVE BENEFITS OF A 4D VIRTUAL SIMULATOR · NA · not yet recruiting
NCT07492251 — Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Ran · Phase 2 · not yet recruiting
NCT07511608 — Development of a New Technique for Quantifying Mitochondrial DNA in Single Muscle Fibers · NA · not yet recruiting
NCT07582406 — Codesign, Physical Activity, and Seniors · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05422521 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nice
Last refreshed: 30 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05422521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing